2023 World Conference on Lung Cancer (Posters)-EP08.02. Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-small Cell Lung Cancer

EP08.02. Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

The standard treatment for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy (cCRT) followed by immune checkpoint inhibitors (ICIs) consolidation. However, many patients are not suitable for ICIs consolidation treatment in real-world conditions. This study aimed to evaluate the efficacy and safety of using induction immunochemotherapy before definitive chemoradiotherapy (CRT) for unresectable LA-NSCLC. <br /><br />From February 2019 to April 2022, 102 patients were enrolled in the study. The median age of the patients was 64 years. The objective response rate (ORR) and disease control rate (DCR) at the end of induction immunochemotherapy were 54.9% and 87.3%, respectively. The ORR of CRT compared to the baseline was 81.4%. The median progression-free survival (PFS) was 20.4 months, with PFS rates of 70.4% at 1 year and 41.9% at 2 years. The overall survival (OS) rates at 1 and 2 years were 92.8% and 76.2%, respectively. <br /><br />Patients receiving concurrent CRT had significantly better OS compared to those receiving sequential CRT. Patients with PD-L1 50% had higher objective response rates and better treatment outcomes compared to those with PD-L1 50%. The most common severe adverse events were hematologic toxicities, and the incidence of grade 3 pneumonitis was only 4.9%. <br /><br />Overall, induction immunochemotherapy followed by definitive CRT showed promising efficacy and tolerable toxicities for unresectable LA-NSCLC. It suggests that this treatment strategy could be an alternative option for these patients.

Asset Subtitle

Leilei Wu

Meta Tag

Speaker Leilei Wu

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

unresectable LA-NSCLC

concurrent chemoradiotherapy

immune checkpoint inhibitors

induction immunochemotherapy

definitive chemoradiotherapy

objective response rate

disease control rate

progression-free survival

overall survival

PD-L1